JLJian Lin

Jian Lin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jian Lin has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Shubai Liu

    State Key Laboratory of Phytochemistry and Natural Medicines, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, Yunnan 650201, China

    2 shared publications
  • Zhicheng He

    Key Laboratory of Plant Resource Conservation and Germplasm Innovation in Mountainous Region (Ministry of Education), College of Life Sciences, Guizhou University, Guiyang 550025, Guizhou Province, P.R. China

    2 shared publications
  • Bo Wang

    School of Business and Management, Lincoln University College, 47301 Selangor, Malaysia

    1 shared publication
  • Cheng Chen

    State Key Laboratory of Phytochemistry and Plant Resources in West China Kunming Institute of Botany, Chinese Academy of Sciences Kunming, Yunnan, PR China

    1 shared publication
  • Chunzhu Gong

    Research and Teaching Department, Shenzhen Pingle Orthopedic Hospital (Shenzhen Pingshan Traditional Chinese Medicine Hospital), Shenzhen, China

    1 shared publication
  • Mingqiang Li

    Laboratory of Biomaterials and Translational Medicine, Center for Nanomedicine, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510630, China

    1 shared publication

Latest Publications

  • Open Access

    Artificial Intelligence in Multimodal Neuroimaging Research on Depression: A Bibliometric Analysis

    by Bo Wang, Xingchen Qiu, Jian Lin, Yin Lian, Chunzhu Gong, Qianqian Yu

    Objective To conduct a systematic bibliometric review of artificial intelligence (AI)-based multimodal neuroimaging research in depression, mapping its evolution, collaborative networks, and intellectual foundations to guide future translation.Methods Records were retrieved from Web of Science Core Collection (search date: 1 September 2025) using terms for depression, neuroimaging modalities, and AI/machine learning (ML)/deep learning. English, peer-reviewed articles/reviews (2001–2025) were screened; 1,232 studies were retained after deduplication and filtering. Analyses included annual output trends, co-authorship networks (countries/institutions/authors), keyword co-occurrence clustering with burst detection, and co-citation/bibliographic coupling using VOSviewer (v1.6.20) and Bibliometrix (v4.5.1).Results Annual publications rose from <20/year to 202 in 2024; 2025 counts (n=173) reflect January–August only. The international network spans 42 countries/regions linked by 320 co-authorship ties (total link strength=1,228; density of approximately 0.37). USA, China, and the UK constitute the epistemic core, with expanding participation from India, Brazil, and Iran. Institutional and author overlays indicate a small-world, hierarchical organization (205 institutions; 10 collaboration communities; author network 168 researchers) characterized by a productive core and long tail. Six keyword clusters delineate a functional workflow: 1) biomarkers/phenotypes, 2) functional connectivity, 3) machine-learning/computational approaches, 4) multimodal/precision psychiatry, 5) diagnostic classification/algorithm development, and 6) structural imaging/comorbidity. Co-citation and coupling reveal a progression from early ML and connectivity foundations to deep/graph models, multimodal fusion, explainability, and treatment-oriented prediction.Conclusion AI-based multimodal neuroimaging in depression has evolved into a coherent, translationally focused field. Current trends emphasize model validation, interpretability, and cross-site generalization, supported by expanding international collaboration. Future priorities include harmonized data sharing, explainable modeling, and theory-informed clinical translation.

  • Open Access

    Polysaccharide Peptide Induced Colorectal Cancer Cells Apoptosis by Down-Regulating EGFR and PD-L1 Expression

    by Lin Jian, He Zhicheng, Liu Shubai

    Background: Colorectal cancer (CRC) is the most frequent death-causing disease in the world. The Trametes versicolor mushroom, a traditional Chinese medicine, has been used as anti-cancer medicine with long history. Its cultured mycelia extracts, namely polysaccharide peptide (PSP) as the major active component in Trametes versicolor, is widely used in eastern countries to stimulate the immune system and treat deadly cancers, including CRC. Methods: This study aimed to explore the mechanism through which PSP inhibits CRC cells proliferation. In vitro, cell proliferation and cytotoxicity of PSP were assessed using human CRC cell lines (HCT116 and HT29). The real-time polymerase chain reaction (PCR), western blot, and immunofluorescence methods were used to examine the expression of epidermal growth factor receptor (EGFR), programmed cell death-ligand 1 (PD-L1), activator of transcription 3 (STAT3), c-Jun, and NF-κB in the PSP treated CRC cells. Human peripheral blood mononuclear cells (PBMC), which were activated with CD3/CD28/CD2 T cell activator and interleukin 2 (IL-2), were co-cultured with HCT116, which was pre-treated with PSP to reduce PD-L1 expression. The synergic effect of T-cells killing was evaluated using the terminal-deoxynucleotidyl transferase-mediated nick-end labeling (TUNEL) method. Results: Polysaccharide peptide significantly inhibited proliferation of HCT116 and HT29 cell line in vitro. Polysaccharide peptide strongly reduced the expression and phosphorylation level of EGFR. In addition, PSP pretreatment significantly decreased the expression of downstream molecules PD-L1 and EGFR signaling pathways (c-Jun and STAT3) in HCT116. Polysaccharide peptide pretreatment enhanced the T-cells killing effect induced by co-culture PBMC on HCT116 cells. Conclusions: Polysaccharide peptide may be used as a prophylactic and therapeutic agent against CRC via down-regulating PD-L1 and EGFR signaling pathway.


  • Open Access

    CtBP1/2 differentially regulate genomic stability and DNA repair pathway in high-grade serous ovarian cancer cell

    by YingYing He, Zhicheng He, Jian Lin, Cheng Chen, Yuanzhi Chen, Shubai Liu

    The C-terminal binding proteins (CtBPs), CtBP1 and CtBP2, are transcriptional co-repressor that interacts with multiple transcriptional factors to modulate the stability of chromatin. CtBP proteins were identified with overexpression in the high-grade serous ovarian carcinoma (HGSOC). However, little is known about CtBP proteins’ regulatory roles in genomic stability and DNA repair in HGSOC. In this study, we combined whole-transcriptome analysis with multiple research methods to investigate the role of CtBP1/2 in genomic stability. Several key functional pathways were significantly enriched through whole transcription profile analysis of CtBP1/2 knockdown SKOV3 cells, including DNA damage repair, apoptosis, and cell cycle. CtBP1/2 knockdown induced cancer cell apoptosis, increased genetic instability, and enhanced the sensitivity to DNA damage agents, such as γ-irradiation and chemotherapy drug (Carboplatin and etoposide). The results of DNA fiber assay revealed that CtBP1/2 contribute differentially to the integrity of DNA replication track and stability of DNA replication recovery. CtBP1 protects the integrity of stalled forks under metabolic stress condition during prolonged periods of replication, whereas CtBP2 acts a dominant role in stability of DNA replication recovery. Furthermore, CtBP1/2 knockdown shifted the DSBs repair pathway from homologous recombination (HR) to non-homologous end joining (NHEJ) and activated DNA-PK in SKOV3 cells. Interesting, blast through TCGA tumor cases, patients with CtBP2 genetic alternation had a significantly longer overall survival time than unaltered patients. Together, these results revealed that CtBP1/2 play a different regulatory role in genomic stability and DSBs repair pathway bias in serous ovarian cancer cells. It is possible to generate novel potential targeted therapy strategy and translational application for serous ovarian carcinoma patients with a predictable better clinical outcome.